LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday that it is ready to enter partnering discussions for its key redeveloped Ibuprofen and Naproxen products, after it finalised commercial discussion materials.
The company said it is now pursuing opportunities to commercialise both products. Oxford Pharmascience's redeveloped versions of the pain-relief and anti-inflammatory drugs are designed to be milder in the gastrointestinal tract and complete mask the bitter taste and burn associated with the drugs.
Oxford Pharmascience noted there can be no certainty that talks will lead to a commercial deal for the assets, or to the terms of any such transaction.
Shares in Oxford Pharmascience were up 9.6% at 5.89 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
